These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26245000)

  • 1. Biologic Medicines Under the Microscope.
    Cauchi R
    State Legis; 2015; 41(7):12. PubMed ID: 26245000
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
    Miller KL; Lanthier M
    Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biosimilar medicines. Scientific and legal disputes].
    Dorantes Calderón B; Montes Escalante IM
    Farm Hosp; 2010 Mar; 34 Suppl 1():29-44. PubMed ID: 20920856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA sets hierarchy for biosimilars evidence.
    Ratner M
    Nat Biotechnol; 2014 Jul; 32(7):609. PubMed ID: 25004221
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars.
    Bagel J
    J Drugs Dermatol; 2014 Jul; 13(7):788-90. PubMed ID: 25007360
    [No Abstract]   [Full Text] [Related]  

  • 6. Frontiers in nonclinical drug development: biosimilars.
    Ryan AM
    Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing shortages of biologic medicines.
    Ramanan S; Grampp G
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):151-9. PubMed ID: 24386902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stakeholders discuss biosimilar naming, substitution.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(6):446-7. PubMed ID: 24589534
    [No Abstract]   [Full Text] [Related]  

  • 9. On the interchangeability of biologic drug products.
    Endrenyi L; Chang C; Chow SC; Tothfalusi L
    Stat Med; 2013 Feb; 32(3):434-41. PubMed ID: 22911936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial steps in the regulation of generic biological drugs: a comparison of U.S. and Canadian regimes.
    Szeto KJ; Wolanski M
    Food Drug Law J; 2012; 67(2):131-41, i. PubMed ID: 24620416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to biosimilar utilization in the United States.
    Dalpoas SE; Socal M; Proctor C; Shermock KM
    Am J Health Syst Pharm; 2020 Nov; 77(23):2006-2014. PubMed ID: 33091103
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing biosimilarity and interchangeability of biosimilar products.
    Chow SC
    Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
    [No Abstract]   [Full Text] [Related]  

  • 15. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 16. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patent watch: Have the biosimilar floodgates been opened in the United States?
    Brinckerhoff CC; Schorr K
    Nat Rev Drug Discov; 2015 May; 14(5):303-4. PubMed ID: 25924576
    [No Abstract]   [Full Text] [Related]  

  • 19. First biosimilar drug set to enter US market.
    Ledford H
    Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
    [No Abstract]   [Full Text] [Related]  

  • 20. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
    Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
    Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.